MTOR and renal cell adenocarcinoma: The approach to RCC treatment has dramatically changed after the appearance of targeted cancer therapy such as multikinase inhibitors [1, 13–15], and several treatment options such as with mammalian target of rapamycin (mTOR) inhibitor have been developed for advanced RCC [16–19].